Overview

Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

Status:
Completed
Trial end date:
2020-09-25
Target enrollment:
Participant gender:
Summary
A Phase 2, uncontrolled, open-label, single arm study to evaluate the safety, tolerability and efficacy of PerioSept® (3%) as adjunct to Scaling and Root Planing in subjects with periodontitis.
Phase:
Phase 2
Details
Lead Sponsor:
Geistlich Pharma AG
Treatments:
Taurolidine